Kornimate/medical-research-clean huggingface dataset:
comparative effects of spider cage therapy and modified suit therapy in cp

Conditions: Cerebral Palsy

Summary: spider cage is a part of universal exercise unit. it is a suspension system, which works with use of belts, elastic cords and thera suits (thera suits especially for cerebral palsy). cords are dynamic and provides an appropriate amount of support with the help of which patient can perform movement independently. cerebral palsy (cp) is a condition where non progressive disorders of posture caused by abnormal development of, or damage to, motor control centers of brain resulting in abnormal movements.

it will be randomized controlled trial in which non probability convenience sampling technique will be used. two groups of 8 to 12 age will be formed in which participants will be randomly divided by lottery method. group a will be given modified thera suits and the other group b will receive spider cage therapy on trunk stability and pelvic control. improvement will be identified by trunk control measurement scale (tcms), trunk impairment scale (tis) and gross motor function classification system. (gmfcs) level i-ii. the result after statistical analysis will show that which treatment will be more effective. results will be analyzed on spss 29. data analyzed by repeated measures anova

Eligibility criteria:
inclusion criteria: * • 8 to 12 years of age * both male and female * hemiplegic cerebral palsy according to (gmfcs) severity level i-ii * ability to follow instructions and participate in therapy session exclusion criteria: * • presence of any medical conditions that would severely limit a child's participation in the study as vision or hearing loss, cardiac anomalies. * severe cognitive impairments that would hinder the participant's ability to actively participate in therapy sessions. * complicated systemic disorders. * uncontrollable seizures. * usage of botulinum toxin a injection within 3 months of prior

Keywords: cp pelvic control spider cage therapy modified thera suits
clinical research of robo1 specific bicar-nk cells on patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. robo1 is a potential target and spectacular paradigm in the treatment of solid tumors. this study is for evaluation of the safety and efficacy of robo1 car-nk cell immunotherapy for pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed metastatic pancreatic adenocarcinoma 2. patients aged between 18 and 75 3. robo1 expression in malignancy tissues detected by immuno-histochemistry (ihc) 4. eastern cooperative oncology group (ecog) performance status of 0 or 1 5. life expectancy greater than 3 months 6. subjects must have measurable disease as defined by recist 1.1 criteria 7. satisfactory organ and bone marrow function: white blood cell count (wbc) ≥ 3.0×10\^9/l, platelets ≥ 70×10\^9/l, hb ≥ 9.0g/dl, lymphocyte (ly) ≥ 0.7×10\^9/l, ly% ≥ 15%, alb ≥ 2.8g/dl, serum lipase and amylase \< 1.5 × upper limit of normal, serum creatinine ≤ 2.5mg/dl, aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dl. these tests must be conducted within 7 days prior to registration 8. karnofsky score ≥ 60 9. ability to give informed consent exclusion criteria: 1. previously treated with any gene therapy products 2. patients who are receiving any other investigational agents 3. women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant 4. active systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other major medical illnesses 5. any form of primary immunodeficiency (such as severe combined immunodeficiency disease) 6. concurrent opportunistic infections
biomarkers for muscle function and aging in chronic hiv infection

Conditions: HIV

Summary: match is an observation study of hiv-infected adults on effective antiretroviral therapy (art) and demographically matched uninfected adults to evaluate muscle and aging.

match is a non-randomized observational longitudinal study. we will recruit hiv infected adults (50 to 65 years old) and demographically matched uninfected control subjects to be followed for 4 years over the course of a 5 year study. the targeted age range of 50-65 is chosen to evaluate aging hiv infected individuals at risk for early frailty in the united states. all subjects will undergo blood draws and physical function assessment, and a subset will undergo a ct scan of muscle and will have a muscle biopsy taken. a substudy will be performed on a subgroup of hiv-infected and hiv-uninfected men from the main cohort to measure daily physical activity by using an activity tracker.

Eligibility criteria:
inclusion criteria: group 1: hiv positive subjects * hiv positive * english speaking * 50-65 years old * on antiretroviral therapy and an hiv viral load below 200 copies/ml * cd4 equal to or greater than 350 cells/mm3 * postmenopausal (women) * lower extremity mobility sufficient to participate in functional assessment. group 2: hiv negative subjects inclusion criteria for group 2 subjects * english speaking * 50-65 years old * negative for hiv (based on an hiv antibody test at study visit 1) * matched to group 1 for sex (50% w, 50% m) and age (50 - 65yo) * postmenopausal (women) * lower extremity mobility sufficient to participate in functional assessment. exclusion criteria: exclusion criteria for group 1 subjects * acute or serious illness within 60 days prior to entry * use of pharmacologic doses of corticosteroids in the past 6 months. * use of anabolic therapy in the past 6 months. * lower extremity mobility insufficient to participate in functional assessment. * current use (last 30 days) of anticoagulants or known bleeding disorder. exclusion criteria for group 2 subjects * acute or serious illness within 60 days prior to entry * use of pharmacologic doses of corticosteroids in the past 6 months * use of anabolic therapy in the past 6 months * lower extremity mobility insufficient to participate in functional assessment * current use (last 30 days) of anticoagulants or known bleeding disorder.
prospective post approval clinical follow-up study of the commercially available u2 knee™ system - "u-propel study"

Conditions: Osteo Arthritis Knee

Summary: the purpose of this study is to evaluate both short and long term clinical performance and safety of the commercially available u2 knee™ system.

this is a prospective, single arm, multi-center, post-approval study designed to evaluate the short and long term clinical performance and safety in subjects receiving primary total knee arthroplasty (tka) with the u2 knee™ system. the study will enroll up to 200 subjects with scheduled pre-discharge, 6-week, 3- and 6-month and up to 5-year annual follow-up visits. study outcomes will be analyzed and published when 1.) all enrolled and implanted subjects complete their 6-week follow up, 2.) all implanted subjects complete their 2-year follow up, 3.) at the conclusion of the study. the study will follow gcp guidelines and will be registered on clinicaltrials.gov.

Eligibility criteria:
inclusion criteria: 1. subject is between 18 and 75 years of age 2. subject is indicated for a unilateral total knee arthroplasty (tka) based on the approved labeling of the device 3. subject has no history of previous prosthetic replacement device or orthopedic surgeries on the operative knee 4. subject is willing and able to provide informed consent to participate in the study; 5. subject is willing and able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits; exclusion criteria: * subjects will be excluded if, in the opinion of the investigator, the subject does not qualify based on approved labeling requirements or subject inclusion criteria.
dapagliflozin in systemic right ventricle (dapa-serve)

Conditions: Dapagliflozin Adverse Reaction; Efficacy; Systemic Right Ventricle

Summary: the purpose of this study is to describe safety and efficacy of dapaglifozin in adults patients with a systemic right ventricle (congenitally corrected transposition of the great arteries or transposition of the great arteries following arterial switch procedure) and impaired systolic function of the systemic right ventricle.

this is a prospective double arm study aiming to describe safety and efficacy of dapaglifozin in adults patients with a systemic right ventricle (congenitally corrected transposition of the great arteries or transposition of the great arteries following arterial switch procedure) and impaired systolic function of the systemic right ventricle. dapagliflozin will be prescribed in a group of randomly selected patients in addition to the optimized medical therapy for heart failure with reduced ejection fraction. changes in quality of life indicators, symptoms, biohumoral markers, exercise capacity and echocardiographic parameters of systolic right ventricular function will be evaluated in comparison with the control group, which will continue standard heart failure therapy.

Eligibility criteria:
inclusion criteria: * age≥18years * optimal medical therapy or at least 3months * systemic right ventricle ejection fraction≤40%, assessed on echocardiography exclusion criteria: * univentricular physiology * systolic blood pressure\<90mmhg * glomerular filtration rate(gfr)\<30ml/min

Keywords: heart failure dapagliflozin systemic right ventricle
smarttouch catheter for left anterior line - smart line study

Conditions: Persistent Atrial Fibrillation

Summary: this prospective, randomized study will investigate, if information of the catheter force during ablation of a left anterior line does reduce total rf application time by prevention of ineffective lesions.

catheter ablation has emerged as a realistic therapeutic option for symptomatic atrial fibrillation (af). the three main techniques described for ablation of persistent af include pulmonary vein (pv) isolation, ablation based on electrogram analysis, and left atrial (la) linear lesions. the ideal endpoint of linear lesions should be complete electrical block; however, this is technically challenging, time consuming, and potentially hazardous. the st catheter combined with 3d mapping and navigation software, gives physicians a real-time, objective measure of tip-to-tissue contact force during the catheter ablation procedure and will allow physicians to more safely and effectively treat atrial fibrillation.

Eligibility criteria:
inclusion criteria: * patients with symptomatic atrial fibrillation and additional substrate modification or perimitral flutter * patients with persistent atrial fibrillation * patients with perimitral flutter * patients with recurrence after a circumferential pv isolation procedure * patients with paroxysmal atrial fibrillation and af episodes lasting \> 7 days * patients (\>18 und \<80 jahre) exclusion criteria: * moderate to severe valvular heart disease, * congenital heart disease * reduced left ventricular function (ejection fraction \<35%) * any reversible cause for atrial fibrillation (e.g. hyperthyroidism) * intracardiac thrombi documented by transesophageal echocardiography * myocardial infarction within 3 months, cardiac surgery in the previous three months

Keywords: smart-touch contact force
study of a quality improvement toolkit in kerala, india, among hospitals treating acute coronary syndrome patients

Conditions: Acute Coronary Syndrome

Summary: the trial assesses the effect on 30-day major adverse cardiovascular event (mace) rate of using a quality improvement toolkit among hospitals in kerala, india. the quality improvement toolkit includes standardized admission and discharge sets, clinical pathways and an audit and feedback program.

this study is a cluster randomized, stepped wedge clinical trial assessing implementation and effect of a locally-developed quality improvement toolkit for patients with acute coronary syndrome (acs) in kerala, india. hospitals will be randomized after stratification for size to one of five cohorts. after a four-month baseline period, the quality improvement toolkit will be implemented in all hospitals in cohort 1. through a one-way crossover design, these hospitals will continue to use the quality improvement toolkit through the end of the trial for all acute coronary syndrome (acs) patients. cohorts 2 through 5 will implement the quality improvement toolkit at time points 8, 12, 16, and 20 months respectively, continuing the use of the toolkits from that time forward to the end of the study. the primary outcome is 30-day mace rates, including death, reinfarction stroke, or major bleeding. rates will be continuously collected and compared at one interim time point for safety and efficacy. final analysis compares mace rates before and after implementation of the quality improvement toolkits, accounting for cluster effects of hospital, cohort and time.

Eligibility criteria:
inclusion criteria: * presenting with acute coronary syndrome exclusion criteria: * below the age of 18 * patient without acute coronary syndrome
evaluation of the salivary-free amino acids levels (glycine , proline , lysine , and alanine ) with caries activity

Conditions: Dental Caries

Summary: this study will be aimed to investigated the correlation between levels of salivary amino acids (glycine , proline , lysine , alanine ) in the saliva of healthy children with and without active carious lesions and to estimate the predictive capacity of caries susceptibility

80 healthy children (8-10 years old) will be recruited from primary schools of baghdad city/ iraq, will be classified according to their level of caries activity (high caries activity, n = 40; negative caries activity, n = 40). total stimulated and unstimulated saliva will be collected to estimate the caries activity by using the snyder test, and amino acid analysis of the saliva will be performed by reversed phase - high performance liquid chromatography (rp-hplc), respectively.

Eligibility criteria:
inclusion criteria: * children aged (8,9,10) years with different caries * absence of signs of gingivitis or periodontal disease. exclusion criteria: * children out the range of age * children with any systemic discases. * children with appliances in the mouth. * children with appliances in the mouth. * children with antibiotic treatment or any other drug over the last two weeks. b

Keywords: salivary -free amino acid measurment
enb guided mwa for early-stage peripheral lung cancer

Conditions: Lung Cancer

Summary: the objective of the study was to evaluate the efficacy and safety of electromagnetic navigation bronchoscopy (enb) guided microwave ablation (mwa) for the treatment of early-stage peripheral lung cancer.

the study is designed as a multi-center prospective trial with one arm. there will be 5 centers participating the study. patients diagnosed with early-stage non-small cell lung cancer (nsclc) that are nonsurgical candidate will be enrolled in the study. sixty patients are expected to be enrolled in the study. the purpose of the study is to evaluate the efficacy and safety of enb guided mwa for the treatment of patients with early-stage nonsurgical nsclc.

Eligibility criteria:
inclusion criteria: 1. patients with peripheral lung nodules demonstrated to be nsclc by pathology with the clinical stage of ia. 2. the length-diameter of the tumors are more than 8 mm and no more than 30 mm. 3. patients are unsuitable for surgery assessed by multi-modality treatment and agree to the primary treatment of ablation. 4. patients have good compliance and sign the informed consent. exclusion criteria: 1. patients cannot receive bronchoscopy for the severe cardiopulmonary dysfunction and other indications. 2. patients have contraindications of general anesthesia. 3. chest ct suggests that navigation bronchoscopy technology cannot guide treatment equipment to reach the peripheral lung lesion. 4. chest ct or bronchoscopy shows that the bronchial lumen occlusion or deformation leading to the guided and treatment equipment cannot reach the peripheral lung lesion. 5. there are large blood vessels or important structures adjacent to peripheral lung lesion. 6. researchers consider the patient do not fit for the study.

Keywords: electromagnetic navigation bronchoscopy(enb) microwave ablation peripheral lung cancer
gut hormone profiling in obese patients with type 2 diabetes (mk-0000-134)

Conditions: Obesity, Morbid; Diabetes Mellitus Type 2

Summary: this study will examine changes in various gut-derived hormones in obese type 2 diabetic patients before and after elective bariatric surgery.


Eligibility criteria:
inclusion criteria: * documented type 2 diabetes with total disease duration ≤10 years * bmi of at least 35 kg/m\^2 * patient is a surgical candidate for either rygbp, gbs or vertical sleeve gastrectomy (vsg) exclusion criteria: * any illness that might confound the results of the study or pose additional risk to the patient by participation * history of stroke, seizures, or other major neurological disorder * history of cancer * patient uses or has used any medication that can alter body weight * patient is unwilling or unable to follow study procedures
antitumoral activity and safety of aezs-108 in women with lhrh receptor positive gynecological tumors

Conditions: Ovarian Cancer; Endometrial Cancer

Summary: the purpose of this study is to determine whether aezs-108 shows anti-tumor activity and is tolerated in patients with gynecological tumors (ovarian / endometrial cancer) that have been shown to express receptors for the luteinizing hormone releasing hormone (lhrh)

the ovary and the endometrium are hormone dependent organs. receptors for different sex hormones are found commonly in epithelial ovarian and endometrial cancers. lhrh and its receptors are expressed in about 80% of human ovarian and endometrial cancers. as binding sites are present on tumors in higher concentrations than on most normal tissues, these receptors represent a specific target for aezs-108 in which doxorubicin is coupled to an lhrh analog. patients whose tumor specimen have shown to be positive for lhrh receptor expression will be investigated for tumor response and tolerability.

Eligibility criteria:
inclusion criteria: * lhrh receptor positive tumor status: positive receptor status determined by immunohistochemistry from primary tumor * histologically confirmed epithelial ovarian cancer (stratum a) * advanced (figo iii or iv) or recurrent disease * progression during treatment with a platinum-based regimen or within 6 months after receiving a platinum-based regimen * previous treatment with a taxane-containing regimen * at least one measurable target lesion (recist criteria) or ca125 level higher than twice the upper limit of normal range (gcig criteria) * histologically confirmed endometrial cancer (stratum b) * advanced (figo iii or iv) or recurrent disease not amenable to potentially curative treatment with local surgery and/or radiation therapy * no previous anthracycline-based chemotherapy * at least one measurable target lesion according to recist criteria

Keywords: lhrh receptor receptor positive tumors platinum resistant ovarian cancer
naltrexone implants as an aid in preventing relapse following inpatient treatment for opioid addiction

Conditions: Opiate Dependence

Summary: the purpose of this clinical trial is to study the efficacy and safety of naltrexone implants as relapse prevention for patients that are completing treatment for opiate addiction in inpatient (or similarly controlled) settings. participants volunteer for the study before being released from inpatient treatment, and are randomized to a naltrexone implant group or a waiting-list control for the duration of the first six months following completion of inpatient treatment. both groups are free to receive treatment as usual (tau) from the norwegian healthcare system. after six months, both groups will be offered to have naltrexone implanted for the remaining six months of the study. the hypotheses are that quality of life, depression, opioid use, will be significantly better in the naltrexone group compared to the non at 6-month follow-up. for the last six months of the trial, the investigators hypothesise that choice of naltrexone implant will mainly strengthen positive tendencies or reverse negative trends on the aforementioned variables. the investigators also hypothesize that the implants can prevent death from opioid overdose up to 6 months after commenced treatment.


Eligibility criteria:
inclusion criteria: * soon to complete inpatient treatment for opioid addiction * living in southern norway exclusion criteria: * psychosis/major depression, currently not treated * pregnancy * liver enzymes: asat or alat \> threefold above upper boundary * maintenance treatment with methadone or buprenorphine

Keywords: substance abuse opiate dependency treatment relapse prevention
"iris shelf" technique for intraocular foreign bodies removal

Conditions: Eye Injuries

Summary: intraocular foreign body (iofb) injury is a common potentially serious form of ocular trauma. metallic iofb is the most common type of iofb injury. apart from the associated ocular tissue damage, metallic iofb may cause permanent visual impairment due to retinal toxicity and endophthalmitis. when presenting posteriorly, the approach of iofb removal is challenging. several techniques had been described for posterior iofb removal. all of these techniques aimed to remove iofb with the least possible collateral damage. this study aims to describe "iris shelf" technique for posterior iofb removal through a clear corneal incision combined with phaco-vitrectomy and report its outcomes.


Eligibility criteria:
inclusion criteria: - posterior segment metallic iofb who underwent combined phacovitrectomy with iofb removal through a clear corneal incision using "iris shelf" technique exclusion criteria: * any other surgical technique for posterior segment iofb removal